Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis

다국어 초록 (Multilingual Abstract)

denosumab treatment in Japanese women with primary osteoporosis or rheumatoid arthritis (RA) with osteoporosis.
Methods: This retrospective study included 143 patients with primary osteoporosis and 96 patients with RA and osteoporosis who were treated with denosumab. Treatment discontinuation, fracture occurrence, lumbar spine (L1e4) bone mineral density (LS-BMD), and bilateral total hip BMD (TH-BMD) were examined before and at 1 and 2 years after treatment commencement.
Results: In the primary osteoporosis group, 32 cases dropped out and no fractures occurred from 0 to 1 year. Eighteen cases were lost to follow-up and no fractures were noted from 1 to 2 years. In the RA with osteoporosis group, 7 cases dropped out and no fracture occurred from 0 to 1 year. Twenty-one cases were lost to follow-up and 2 nonvertebral fractures were noted from 1 to 2 years. In this group, 13 cases dropped out from 1 to 2 years and 16 cases dropped out during the 2-year study period due to economic reasons. LS-BMD and TH-BMD values increased continuously for 2 years of treatment in both primary osteoporosis and RA with osteoporosis groups.
Conclusions: These results suggest that during denosumab therapy, the discontinuation rate is expected to remain low during 2 years of treatment in primary osteoporotic patients. In RA patients with osteoporosis, however, the discontinuation rate may increase due to economic reasons from 1 to 2 years of therapy.

참고문헌 (Reference)

1 Watt J, "There is still a care gap in osteoporosis management for patients with rheumatoid arthritis" 81 : 347-351, 2014

2 Papapoulos S, "The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study" 26 : 2773-2783, 2015

3 Kamimura M, "Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients" 28 : 559-566, 2017

4 Orimo H, "Japanese 2011guidelines for prevention and treatment of osteoporosis: executive summary" 7 : 3-20, 2012

5 Hadji P, "GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab" 27 : 2967-2978, 2016

6 Takeuchi T, "Effect of denosumab on Japanese patients with rheumatoid arthritis: a doseresponse study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebocontrolled, phase II clinical trial" 75 : 983-990,

7 Blouin J, "Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004among osteoporotic women" 92 : 887-894, 2007

8 Leder BZ, "Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATASwitch study): extension of a randomised controlled trial" 386 : 1147-1155, 2015

9 van der Linden MP, "Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria" 63 : 37-42, 2011

10 Nakamura Y, "Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study" 15 : 81-, 2015